Off-Label Use of Biologic Agents in the Treatment of Dermatosis, Part 2: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab, and Cetuximab

Statistics

Review article

Uso de Fármacos Biológicos en Dermatosis Fuera de la Indicación Aprobada. Segunda Parte: Etanercept, Efalizumab, Alefacept, Rituximab, Daclizumab, Basiliximab, Omalizumab y Cetuximab

G. Guhl

Corresponding author

guhl@aedv.es

Correspondence: Servicio de Dermatología, Hospital Universitario de la Princesa, Diego de León, 62, 28006 Madrid, Spain.

, B. Díaz-Ley, J. Fernández-Herrera

Servicio de Dermatología, Hospital Universitario de la Princesa, Madrid, Spain

Read

7437

Times
was read the article

3240

Total PDF

4197

Total HTML

Share statistics

Article information

ISSN: 15782190
Original language: English

DOI:10.1016/S1578-2190(08)70191-4

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 May	46	32	78
2024 April	69	37	106
2024 March	92	52	144
2024 February	59	33	92
2024 January	47	42	89
2023 December	62	30	92
2023 November	44	42	86
2023 October	34	21	55
2023 September	53	37	90
2023 August	25	39	64
2023 July	37	57	94
2023 June	52	36	88
2023 May	37	34	71
2023 April	23	22	45
2023 March	29	19	48
2023 February	31	20	51
2023 January	45	28	73
2022 December	46	38	84
2022 November	22	30	52
2022 October	36	22	58
2022 September	26	28	54
2022 August	50	52	102
2022 July	24	31	55
2022 June	22	38	60
2022 May	41	57	98
2022 April	49	40	89
2022 March	55	59	114
2022 February	58	23	81
2022 January	65	42	107
2021 December	62	40	102
2021 November	41	39	80
2021 October	33	47	80
2021 September	40	40	80
2021 August	34	33	67
2021 July	29	29	58
2021 June	22	31	53
2021 May	31	31	62
2021 April	94	74	168
2021 March	67	27	94
2021 February	50	34	84
2021 January	47	20	67
2020 December	27	21	48
2020 November	36	24	60
2020 October	28	9	37
2020 September	31	14	45
2020 August	24	27	51
2020 July	33	7	40
2020 June	27	29	56
2020 May	25	28	53
2020 April	26	18	44
2020 March	33	27	60
2020 February	5	8	13
2020 January	0	5	5
2019 December	0	10	10
2019 November	0	9	9
2019 October	0	13	13
2019 September	0	18	18
2019 August	0	8	8
2019 July	0	16	16
2019 June	0	17	17
2019 May	1	65	66
2019 April	0	25	25
2019 March	0	14	14
2019 February	0	17	17
2019 January	0	8	8
2018 December	0	8	8
2018 April	0	4	4
2018 March	0	5	5
2018 February	13	11	24
2018 January	25	14	39
2017 December	28	22	50
2017 November	19	11	30
2017 October	22	16	38
2017 September	27	21	48
2017 August	39	8	47
2017 July	39	13	52
2017 June	51	32	83
2017 May	51	18	69
2017 April	43	14	57
2017 March	46	40	86
2017 February	29	17	46
2017 January	27	23	50
2016 December	46	15	61
2016 November	44	17	61
2016 October	43	25	68
2016 September	50	14	64
2016 August	46	17	63
2016 July	62	23	85
2016 June	19	12	31
2016 May	10	23	33
2016 April	7	1	8
2016 March	5	7	12
2016 February	13	1	14
2016 January	15	9	24
2015 December	12	9	21
2015 November	14	13	27
2015 October	9	3	12
2015 September	9	6	15
2015 August	7	5	12
2015 July	25	16	41
2015 June	44	23	67
2015 May	89	34	123
2015 April	41	35	76
2015 March	52	13	65
2015 February	28	25	53
2015 January	46	24	70
2014 December	38	24	62
2014 November	33	20	53
2014 October	41	20	61
2014 September	42	33	75
2014 August	40	23	63
2014 July	52	27	79
2014 June	38	12	50
2014 May	49	16	65
2014 April	48	14	62
2014 March	35	22	57
2014 February	30	28	58
2014 January	25	28	53
2013 December	41	29	70
2013 November	34	20	54
2013 October	31	31	62
2013 September	29	38	67
2013 August	28	30	58
2013 July	33	47	80
2013 June	23	66	89
2013 May	45	43	88
2013 April	30	53	83
2013 March	40	26	66
2013 February	53	17	70
2013 January	19	3	22

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter